Early-phase clinical trials in a pandemic: learning from the response to COVID-19
Lancet Respir Med
.
2022 Jul;10(7):625-627.
doi: 10.1016/S2213-2600(22)00062-5.
Epub 2022 Jun 13.
Authors
Alex Horsley
1
,
Chris Brightling
2
,
Jane Davies
3
,
Ratko Djukanovic
4
,
Liam G Heaney
5
,
Tracy Hussell
1
,
Stefan J Marciniak
6
,
Lorcan McGarvey
5
,
Joanna C Porter
7
,
Thomas Wilkinson
4
,
Ling-Pei Ho
8
;
NIHR Respiratory Translational Research Collaboration network
Affiliations
1
Division of Infection, Immunity and Respiratory Medicine, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.
2
Leicester NIHR Biomedical Research Centre and Department of Respiratory Sciences, University of Leicester, Leicester, UK.
3
Royal Brompton and Harefield NHS Foundation Trust and Imperial College London, London UK.
4
NIHR Southampton Biomedical Research Centre and School of Clinical and Experimental Sciences, University of Southampton, Southampton, UK.
5
Wellcome Wolfson Institute for Experimental Medicine, Queens University, Belfast, UK.
6
Cambridge University Hospitals NHS Foundation Trust, Royal Papworth Hospital NHS Foundation Trust, and University of Cambridge, Cambridge, UK.
7
UCL Department of Respiratory Medicine, UCL, and UCLH NHS Foundation Trust, London, UK.
8
Oxford NIHR Biomedical Research Centre and MRC Human Immunology Unit, University of Oxford, Oxford, UK. Electronic address:
[email protected]
.
PMID:
35709826
PMCID:
PMC9191862
DOI:
10.1016/S2213-2600(22)00062-5
No abstract available
Publication types
Comment
MeSH terms
COVID-19*
Humans
Pandemics*
SARS-CoV-2